Goldman Sachs reiterates a Conviction Buy rating on Alexion Pharmaceuticals (ALXN) and adds $13...


Goldman Sachs reiterates a Conviction Buy rating on Alexion Pharmaceuticals (ALXN) and adds $13 to take its price target on shares to $105. The firm sees a clear win for Alexion off of published studies in the New England Journal of Medicine on the success of its Soliris drug in treating rare kidney diseases.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs